Holen Sie sich die Stockscreener-App
67.55
0.10%
0.07
Handel nachbörslich:
67.15
-0.40
-0.59%
Schlusskurs vom Vortag:
$67.48
Offen:
$67.54
24-Stunden-Volumen:
1.14M
Relative Volume:
0.87
Marktkapitalisierung:
$5.70B
Einnahmen:
$4.04M
Nettoeinkommen (Verlust:
$-161.00M
KGV:
-32.44
EPS:
-2.0823
Netto-Cashflow:
$-132.48M
1W Leistung:
+5.61%
1M Leistung:
+9.16%
6M Leistung:
+77.16%
1J Leistung:
+292.73%
1-Tages-Spanne:
$66.90
$68.90
1-Wochen-Bereich:
$65.02
$69.30
52-Wochen-Spanne:
$14.80
$69.35
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
67.55 | 5.70B | 4.04M | -161.00M | -132.48M | -2.0823 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Wedbush | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
CEO Moves: Can CG Oncology Inc expand into new markets2026 Buyback Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade) - Seeking Alpha
CG Oncology stock hits all-time high at 60.01 USD By Investing.com - Investing.com Australia
CG Oncology Stock Surges on Fresh Institutional Backing - TipRanks
CGON PE Ratio & Valuation, Is CGON Overvalued - Intellectia AI
Aug Action: What is the target price for CG Oncology Inc stock2026 EndofYear Setup & Consistent Return Strategy Ideas - baoquankhu1.vn
Trade Recap: Can CG Oncology Inc expand into new markets - baoquankhu1.vn
Portfolio Recap: Is CG Oncology Inc impacted by rising ratesMarket Weekly Review & Expert Approved Momentum Ideas - baoquankhu1.vn
CG Oncology, Inc. $CGON Stake Lifted by JPMorgan Chase & Co. - marketbeat.com
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know - AOL.com
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Downgraded by Wall Street Zen to Sell - marketbeat.com
CG Oncology, Inc. (NASDAQ:CGON): Are Analysts Optimistic? - 富途牛牛
Vanguard realignment reports 0% ownership in CG Oncology (CGON) - Stock Titan
UBS raises CG Oncology stock price target to $90 on trial outlook - Investing.com India
UBS Adjusts Price Target on CG Oncology to $90 From $60, Maintains Buy Rating - MarketScreener
UBS raises CG Oncology stock price target to $90 on trial outlook By Investing.com - za.investing.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
Kynam Capital Cuts CG Oncology Holding: Q4 2025 Sale Details & ImpactNews and Statistics - IndexBox
This Biotech Stock Surged 135% but Just Saw a $44 Million Sell-Off. What Does This Mean for Investors? - bitget.com
CGON Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Friday - marketbeat.com
Quarterly Trades: Can CG Oncology Inc deliver consistent EPS growth2026 Key Highlights & Real-Time Price Movement Reports - baoquankhu1.vn
Why CG Oncology Stock Is Suddenly Losing Steam - TipRanks
CG Oncology, Inc. Hits New 52-Week High of $59.95 - Markets Mojo
Highs Report: What is the dividend yield of CG Oncology IncWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
Dividend Watch: Is CG Oncology Inc impacted by rising rates2026 Earnings Surprises & Community Trade Idea Sharing - baoquankhu1.vn
Will CG Oncology Inc outperform tech stocksEarnings Miss & Growth Oriented Trade Recommendations - baoquankhu1.vn
CG Oncology (NASDAQ:CGON) Director James Mulay Sells 1,964 Shares - MarketBeat
CG Oncology (NASDAQ: CGON) director sells 1,964 shares after option exercises - Stock Titan
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Protagonist Therapeutics (PTGX) and CG Oncology, Inc. (CGON) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology, Inc. $CGON Stake Increased by HighVista Strategies LLC - MarketBeat
Boothbay Fund Management LLC Has $3.81 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ:CGON) Reaches New 52-Week HighShould You Buy? - MarketBeat
ArrowMark Colorado Holdings LLC Has $10.36 Million Holdings in CG Oncology, Inc. $CGON - MarketBeat
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts - simplywall.st
CG Oncology stock hits all-time high at 63.9 USD By Investing.com - Investing.com Nigeria
Is CG Oncology (CGON) Pricing Reflect Its Recent 131% Surge And Cancer Breakthrough Hopes - Yahoo Finance
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade - MSN
Mangrove Partners IM LLC Increases Stock Position in CG Oncology, Inc. $CGON - MarketBeat
Form 4 CG Oncology Inc For: 14 March - Investing.com
CG Oncology (NASDAQ: CGON) CEO net exercises options and increases share stake - Stock Titan
Rosalind Advisors Inc. Grows Holdings in CG Oncology, Inc. $CGON - MarketBeat
Is It Too Late To Consider CG Oncology (CGON) After A 143% One Year Surge? - simplywall.st
CG Oncology stock rallies nearly 32% in a week: Here is why - MSN
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):